A Phase II Study of Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer

Full Title

Phase II Study of Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients with Muscle-Invasive Bladder Cancer Back to top


Studies have shown that giving the cisplatin-based chemotherapy before bladder removal surgery in patients with bladder cancer that has invaded the nearby muscle helps patients live longer than if they had surgery alone. The combination of cisplatin and gemcitabine is commonly used in this setting. The purpose of this study is to evaluate the safety and effectiveness of giving gemcitabine and cisplatin in a “dose-dense” schedule before bladder removal surgery in patients with muscle-invasive bladder cancer.

Dose-dense chemotherapy means the anticancer drugs are given more frequently than the standard treatment regimen. Some studies suggest that patients with cancer who receive dose-dense chemotherapy that includes cisplatin live longer than those who receive chemotherapy according to the standard dosing schedule.

Back to top


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have muscle-invasive bladder cancer and be candidates for bladder removal surgery (radical cystectomy).
  • Patients may not have previously received chemotherapy or radiation therapy for their bladder cancer. Intravesical therapy is allowed.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Dean Bajorin at 646-422-4333.

Back to top